U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals: financial performance was affected by weather and increased expenses, leading to a decrease in net income and cash reserves. However, the company maintains confidence in achieving its annual guidance and sees potential in hospital partnerships. The Q&A reveals concerns about unpredictable hospital deals and management's avoidance of detailed guidance. The market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, with positive long-term strategies offset by short-term financial challenges.
Key Financial Performance
Total Revenue $198 million, a 7.9% increase versus 2025. This growth was driven by a 6.9% increase in total patient visits and a $0.83 increase in net patient revenue per visit.
Physical Therapy Revenue $168 million, a 7.2% increase versus prior year first quarter. Mature clinic revenue increased 2.5%, continuing the sequential quarter-over-quarter build from 2025.
Net Patient Revenue Per Visit $106.49, an $0.83 increase versus the prior year. This growth was driven by a 3.4% increase in commercial revenue per visit and a 1.75% Medicare rate increase.
Daily Visits Per Clinic 31.8 in the first quarter 2026 compared to 31.2 in Q1 2025, driven by a 6.9% increase in total patient visits.
Injury Prevention Revenue $31 million, an 11.8% increase versus the prior year. Excluding the Q1 2026 IIP acquisition, IIP revenue increased 8.2%. IIP margin increased to 20.4% in Q1 2026 compared with 18.6% in Q1 2025.
Adjusted Physical Therapy Payroll Cost Per Visit $64.20 in the first quarter of 2026 compared to $63.53 in the first quarter of 2025, reflecting increased costs.
Adjusted Physical Therapy Operating Cost Per Visit $90.31 in the first quarter of 2026 compared to $88.77 in the first quarter 2025, reflecting increased costs.
Adjusted Physical Therapy Margin 16.1% in Q1 2026 compared to 16.8% in Q1 2025, reflecting a decrease due to higher costs.
Adjusted Corporate Expense as a Rate to Revenue 8.8% in Q1 2026 compared to 8.5% in Q1 2025, reflecting a slight increase.
Interest Expense $2.8 million in the first quarter of 2026 compared to $2.3 million in Q1 2025, driven by cash usage associated with acquisitions and purchases of non-controlling interest.
Income Tax Rate 32.3% in Q1 2026 compared to 28.1% in Q1 2025, elevated due to the negative impact of discrete tax items on comparatively lower pretax income.
Adjusted EBITDA $20.2 million, a $0.7 million increase compared to Q1 2025, reflecting improved operational performance.
Net Income Attributable to Shareholders $5 million in Q1 2026 compared to $9.9 million for Q1 2025, reflecting a decrease due to a loss on change in fair value of contingent earn-out considerations.
GAAP Loss Per Share $0.12 in the first quarter 2026 compared to earnings per share of $0.80 in the first quarter of 2025, negatively impacted by revaluation of redeemable non-controlling interest.
Cash and Cash Equivalents $28 million at the end of Q1 2026 compared to $36 million at the end of 2025, reflecting a decrease due to acquisitions and purchases of non-controlling interest.
Borrowings on Credit Facility $204 million in Q1 2026 compared to $162 million at the end of 2025, driven by acquisitions and purchases of non-controlling interest.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Semi-virtualization of front desk: Implemented to produce savings in labor, improve efficiency, and enhance authorization consistency.
AI-assisted ambient listening documentation technology: Introduced to reduce clinicians' time on computers, potentially increasing productivity and patient interaction.
Remote therapeutic monitoring for Medicare population: Reengaged after CMS rule revisions in January 2026.
Expansion of cash-based programs: Rolled out across top partnerships to drive growth.
Partnership with large hospitals and systems: Initiated partnerships with NYU and another Gulf Coast region hospital, with clinic transitions underway.
Nine-Clinic therapy partnership in Pacific Northwest: Added to the portfolio, expected to perform well.
Seven de novo clinics: Opened in Q1 2026, with more planned.
Revenue growth in physical therapy: Increased by 7.3% with a 2.5% same-store increase, driven by a 6.9% rise in patient volume.
Injury prevention revenue growth: Increased by 11.8%, with an 8.2% same-store revenue increase and a 180 basis point margin improvement.
Credit facility renegotiation: Secured a five-year $450 million facility with improved pricing and terms, expanding capacity for growth investments.
Workday ERP implementation: Progressing for a 2027 launch to modernize systems and improve efficiency.
Equity repurchase in partnerships: Invested over $14 million in two strong partnerships, maintaining a robust owner base.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Weather-related disruptions: The company lost over 31,000 visits due to weather events, impacting revenue and margins as staff had to be paid despite not working.
Medicaid rate decline: A small drop in Medicaid rates was noted, which could have a negative impact on blended revenue rates if it continues.
Increased operating costs: Adjusted physical therapy payroll and operating costs per visit increased compared to the previous year, potentially pressuring margins.
Higher interest expenses: Interest expenses increased due to acquisitions and purchases of non-controlling interests, which could impact net income.
Elevated income tax rate: The income tax rate increased to 32.3% from 28.1% in the prior year, negatively affecting net income.
Redeemable non-controlling interest impact: Stronger performance increased the value of redeemable non-controlling interests, negatively impacting per-share metrics.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Reaffirmation of 2026 Guidance: The company reaffirmed its full-year 2026 adjusted EBITDA guidance of $102 million to $106 million, indicating confidence in achieving its financial targets.
Revenue Growth Expectations: The company expects continued revenue growth driven by increased patient visits, higher commercial rates, and Medicare rate increases. The impact of hospital affiliations is expected to further enhance revenue later in the year.
Operational Efficiency Initiatives: The company is implementing semi-virtualization of front desk operations and AI-assisted documentation technology to improve labor efficiency, productivity, and authorization consistency.
Expansion Plans: Plans include expanding cash-based programs across top partnerships, increasing collaborations with large hospitals and systems, and opening new clinics. The NYU hospital partnership is expected to accelerate growth in 2026 and beyond.
Capital Structure and Growth Investments: The company secured a $450 million credit facility to support growth initiatives, including acquisitions and technology investments, without compromising operational flexibility.
Workday ERP Implementation: The company plans to implement Workday ERP for human resources and finance by early 2027 to modernize systems and improve efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Repurchase of Equity: In the quarter, the company repurchased equity in two strong partnerships with a total spend of a little more than $14 million. This was done where the company continues to have strong founding partners who are taking some chips off the table due to their extraordinary growth over time in one case and another at a point of planned retirement with a strong owner base still intact.
Credit Facility for Shareholder Returns: The company announced a five-year $450 million credit facility with a maturity date of April 14, 2031. This larger facility compared to the previous $325 million facility provides additional flexibility to grow the portfolio of partnerships and return capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How did the Q1 performance compare to the company's original expectations, and what were the key factors affecting it?
A:The Q1 performance came in almost exactly as budgeted. Key factors included a $3.3 million revenue impact due to weather, which caused the loss of 31,000 visits, particularly in high net rate markets like New York. Despite this, demand remained high, and investments in initiatives are expected to yield positive results.
Q:How should we think about the ramp for the rest of the year, and what are the key contributors to achieving the full-year guidance?
A:The company expects sequential ramp-up throughout the year. Hospital alliances and acquisitions are included in the guidance, with hospital contributions expected to ramp up by Q4. The company is confident in achieving the $102 million to $106 million guidance, despite Q1 EBITDA being slightly lower than typical seasonality.
Q:What drove the year-over-year growth in rent, supplies, and corporate expenses?
A:The growth was driven by higher contract labor costs in some partnerships due to volume, upfront investments in 2026 initiatives, and weather-related impacts that caused deleveraging on fixed costs. These impacts are expected to normalize as weather improves and initiatives ramp up.
Q:What is the company's confidence level in hospital partnerships and M&A activity for the year?
A:The company is confident in more hospital partnerships and M&A activity, citing a strong pipeline and ongoing conversations. However, the cadence of these deals is unpredictable due to the complexity of negotiations with large institutions.
Q:What is the potential scale of hospital alliances over the next three to five years?
A:The company sees significant potential in hospital alliances, with opportunities larger than the NYU deal. While exact numbers are uncertain, the company expects these alliances to become a substantial part of its business.
Q:How did weather impact Q1 volumes, and how are volumes trending now?
A:Weather caused the loss of 31,000 visits in Q1. Volumes have rebounded nicely in April and are progressing well, indicating a strong start to the busier season.
Q:What is the outlook for pricing and Medicaid's impact on revenue?
A:Pricing is expected to build throughout the year, with Medicare adjustments catching up to the 1.7% increase. Medicaid, which is a small part of the business, showed a slight decline, but its impact is not expected to be significant.
Q:What is the expected trend for operating costs per visit as volumes normalize?
A:Operating costs per visit are expected to normalize as weather impacts subside and volumes increase. Improved employee retention, with turnover now below 18%, is also expected to positively impact costs.
Q:What is the company's approach to cash-based programs, and what are the key offerings?
A:The company is focusing on cash-based programs like laser treatments, shockwave therapy, and dry needling, which have strong clinical efficacy and patient demand. These programs are gaining traction and are expected to contribute significantly to revenue.
Q:What is the company's strategy for hospital alliances and their potential impact?
A:The company is targeting both large and smaller hospital alliances, with some opportunities larger than the NYU deal. These alliances are expected to have a significant impact on the business, especially in partnerships where the company has a higher ownership stake.
Q:Review of Unclear Management Responses
A:Management avoided providing specific month-by-month breakdowns of weather-related visit losses and detailed quarterly guidance. They also did not fully clarify the impact of Medicaid pricing changes, citing the need for further analysis.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI ambient
Accounting detail
Accounting process
America Regions
Bank BankUnited
Clinic
Finance Accounting
Interim CFO
NYU
acquisition purchase
beginning
borrowing
capital
cash program
clinician
confidence
development
difference life
earn
efficiency
expense
increase visit
lender
loss
majority
maturity date
meeting
objective
opportunity hospital
patient visit
progress
purchase interest
store
tax
technology
visit increase
visit therapy
USPH Transcript
U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary shows mixed signals: financial performance was affected by weather and increased expenses, leading to a decrease in net income and cash reserves. However, the company maintains confidence in achieving its annual guidance and sees potential in hospital partnerships. The Q&A reveals concerns about unpredictable hospital deals and management's avoidance of detailed guidance. The market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, with positive long-term strategies offset by short-term financial challenges.
U.S. Physical Therapy, Inc. (USPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call showed strong financial performance with increased revenues, margins, and EBITDA. The Q&A highlighted positive growth prospects, efficient cost management, and strategic acquisitions. Despite some concerns about wage inflation and unclear details on hospital rates, the company's optimistic guidance, improved margins, and strategic initiatives like AI-driven operations and acquisitions suggest a positive outlook. Given the company's market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.
U.S. Physical Therapy, Inc. (USPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance, with significant revenue and margin growth, and positive developments in acquisitions and injury prevention. The Q&A indicates solid demand and effective labor management strategies, with AI tools enhancing efficiency. The introduction of a buyback program and slight commercial rate increases further boost sentiment. While there are some uncertainties, such as Medicare rate changes and staffing challenges, the overall outlook is optimistic. Given the company's small-cap status, the positive factors are likely to result in a stock price increase of 2% to 8%.
USPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
